When is JANX's latest earnings report released?
The most recent financial report for Janux therapeutics, inc. (JANX) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating JANX's short-term business performance and financial health. For the latest updates on JANX's earnings releases, visit this page regularly.
How much debt does JANX have?
As of the end of the reporting period, Janux therapeutics, inc. (JANX) had total debt of 22.14M, with a debt ratio of 0.02. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does JANX have?
At the end of the period, Janux therapeutics, inc. (JANX) held Total Cash and Cash Equivalents of 53.15M, accounting for 0.05 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does JANX go with three margins increasing?
In the latest report, Janux therapeutics, inc. (JANX) did not achieve the “three margins increasing” benchmark, with a gross margin of -13.45%%, operating margin of -538.08%%, and net margin of -964.31%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess JANX's profit trajectory and future growth potential.
Is JANX's EPS continuing to grow?
According to the past four quarterly reports, Janux therapeutics, inc. (JANX)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.51. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of JANX?
Janux therapeutics, inc. (JANX)'s Free Cash Flow (FCF) for the period is -28.65M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 70.86% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
What are the PEG ratio and PE ratio of JANX?
The latest valuation data shows Janux therapeutics, inc. (JANX) has a Price-To-Earnings (PE) ratio of -7.39 and a Price/Earnings-To-Growth (PEG) ratio of -0.09. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.
